A new study with ‘real world’ data shows greater efficacy of Victoza(R)
11 June 2012 | By Novo Nordisk
New data show that Victoza® provided greater reductions in HbA1c...
List view / Grid view
11 June 2012 | By Novo Nordisk
New data show that Victoza® provided greater reductions in HbA1c...
Eli Lilly and Company and Incyte Corporation announced the presentation of 12-week results from a Phase IIb study of baricitinib, formerly LY3009104 (INCB28050), an orally available janus kinase (JAK) inhibitor, in patients with active rheumatoid arthritis (RA).
11 June 2012 | By Roche
Roche announced that the U.S. FDA has approved PerjetaTM (pertuzumab)...
11 June 2012 | By Novartis
New long-term data for Gilenya®...
11 June 2012 | By Boehringer Ingelheim
Eli Lilly and Company and Boehringer Ingelheim announced results from two Phase II studies...
9 June 2012 | By GlaxoSmithKline
Detailed 52 and 32-week data from the first two Phase III studies...
9 June 2012 | By AstraZeneca
AstraZeneca and Bristol-Myers Squibb Company announced results from a Phase 3 clinical study...
8 June 2012 | By GlaxoSmithKline
GSK has extended its tender offer to acquire all of the outstanding shares of HGS...
8 June 2012 | By Amgen
Amgen announced top-line results of the Phase 3 EVOLVE(TM) trial...
8 June 2012 | By Novo Nordisk
Regulatory review period extended for insulins degludec & insulin degludec/insulin aspart...
Tecan has signed a co-marketing agreement with Reinnervate, a leading company in the 3D cell culture market, to develop a range of automated solutions based on the Freedom EVO® liquid handling workstations and Reinnervate’s Alvetex®Scaffold 3D cell culturing technology.
7 June 2012 | By Publicis Life Brands Resolute
New efficacy and safety data...
7 June 2012 | By Phenomenex Inc
Phenomenex proudly marks its 30th anniversary in 2012...
7 June 2012 | By GlaxoSmithKline
The US FDA has approved Horizant® (gabapentin enacarbil)...
6 June 2012 | By BASF
Metanomics Health GmbH is launching MetaMap®Tox...